Zacks Research Analysts Lift Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a note issued to investors on Wednesday, January 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $0.61 per share for the quarter, up from their previous estimate of $0.60. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's FY2025 earnings at $2.68 EPS, Q2 2026 earnings at $0.84 EPS and Q3 2026 earnings at $0.89 EPS.

Other equities analysts also recently issued reports about the company. Evercore ISI lowered their price objective on BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 30th. Raymond James restated an "outperform" rating and issued a $79.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, October 10th. Robert W. Baird lowered their target price on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a report on Wednesday, October 30th. Barclays cut their target price on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an "overweight" rating for the company in a research note on Friday, October 4th. Finally, Wedbush raised shares of BioMarin Pharmaceutical to a "strong-buy" rating in a report on Monday, November 4th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.20.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock traded down $1.00 on Friday, hitting $67.38. 1,227,980 shares of the stock traded hands, compared to its average volume of 1,131,029. The firm has a market cap of $12.84 billion, a price-to-earnings ratio of 40.35, a PEG ratio of 0.65 and a beta of 0.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The firm has a 50 day simple moving average of $65.81 and a two-hundred day simple moving average of $75.23. BioMarin Pharmaceutical has a 52 week low of $61.15 and a 52 week high of $96.64.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The firm had revenue of $746.00 million during the quarter, compared to analysts' expectations of $703.37 million. During the same period in the prior year, the company posted $0.26 earnings per share. The company's revenue was up 28.4% compared to the same quarter last year.

Institutional Trading of BioMarin Pharmaceutical

Large investors have recently modified their holdings of the company. Erste Asset Management GmbH bought a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at $48,527,000. Vestal Point Capital LP purchased a new stake in BioMarin Pharmaceutical in the third quarter worth about $28,116,000. Clearline Capital LP bought a new position in BioMarin Pharmaceutical during the 3rd quarter worth about $22,477,000. Dimensional Fund Advisors LP grew its holdings in BioMarin Pharmaceutical by 38.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company's stock worth $85,178,000 after acquiring an additional 289,953 shares in the last quarter. Finally, Bellevue Group AG increased its position in BioMarin Pharmaceutical by 533.7% during the 3rd quarter. Bellevue Group AG now owns 330,976 shares of the biotechnology company's stock valued at $23,264,000 after purchasing an additional 278,744 shares during the period. Hedge funds and other institutional investors own 98.71% of the company's stock.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the company's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the transaction, the executive vice president now directly owns 68,909 shares in the company, valued at $4,573,490.33. This represents a 7.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.85% of the stock is owned by corporate insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.